Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program

Hoth Therapeutics (NASDAQ: HOTH) deployed the OpenAI API to support IND-enabling development of HT-KIT, its orphan-designated therapy for rare KIT-driven cancers.

Rhea-AI Summary

Hoth Therapeutics (NASDAQ: HOTH) deployed the OpenAI API to support IND-enabling development of HT-KIT, its orphan-designated therapy for rare KIT-driven cancers. Key preclinical findings include >80% KIT mRNA/protein suppression, statistically significant tumor-volume reduction by Day 8, and no dose-limiting toxicities reported.

GLP-validated bioanalytical methods are complete and HT-KIT is advancing toward IND submission and Phase 1 clinical evaluation.

Positive

• >80% KIT mRNA/protein reduction in preclinical models
• Statistically significant tumor-volume reduction by Day 8
• No dose-limiting toxicities observed in reported preclinical work
• GLP-validated bioanalytical methods completed to support IND
• Received Orphan Drug Designation for HT-KIT

Negative

• Program remains preclinical: no human clinical data yet
• IND submission and Phase 1 enrollment not yet completed

Argus Mar 4 session

+3.33% close to close Open Argus

Details

News Market Reaction – HOTH

On Mar 4, the day this news came out, HOTH closed 3.33% above the previous close.

Data tracked by StockTitan Argus for the Mar 4 session.

Market Context

This announcement highlights deeper integration of AI, via the OpenAI API, into HT-KIT’s IND-enablin...

Analysis

This announcement highlights deeper integration of AI, via the OpenAI API, into HT-KIT’s IND-enabling workflow, including data analysis, molecular modeling, and regulatory preparation. Preclinical signals show >80% KIT suppression, early anti-tumor activity by Day 8, and no reported dose-limiting toxicities, with GLP-validated bioanalytics in place. In context of prior NVIDIA and Lantern AI collaborations, investors may watch for IND submission timing, Phase 1 design details, and any capital raises under the existing $50 million shelf.

Key Figures

KIT suppression: >80% reduction Tumor response timing: Day 8 Dose-limiting toxicities: 0 observed +1 more

KIT suppression

>80% reduction

KIT mRNA/protein across in-vitro and in vivo models

Tumor response timing

Day 8

Statistically significant tumor-volume reduction in xenograft models by Day 8

Dose-limiting toxicities

0 observed

No dose-limiting toxicities in reported preclinical work

Development stage

Phase 1 planned

HT-KIT advancing toward IND submission and Phase 1 evaluation

Previous AI Reports

4 past events · Latest: Nov 20

Same Type 4 events

1. Nov 20

   NVIDIA Connect program

   24h Move

   -10.4%

   Joined NVIDIA Connect to enhance GPU-accelerated AI tools for multiple programs.

2. Oct 08

   NVIDIA AI licenses

   24h Move

   +3.3%

   Expanded NVIDIA AI Enterprise licenses to support broad AI-driven drug development.

3. Sep 04

   PredictBBB.ai adoption

   24h Move

   +0.8%

   Adopted PredictBBB.ai with 94% accuracy to assess BBB permeability in R&D.

4. Mar 27

   Merveille.ai obesity AI

   24h Move

   -7.4%

   Advanced AI-driven discovery for obesity through wholly owned Merveille.ai unit.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase 1, xenograft models, glp-validated, pharmacokinetic, +3 more

7 terms

phase 1 medical

"HT-KIT is advancing toward Investigational New Drug (IND) submission and Phase 1 clinical"

Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.

xenograft models medical

"Rapid anti-tumor activity: In xenograft models, statistically significant tumor-volume"

Xenograft models are laboratory tests in which human tissues or tumors are implanted into animals (commonly mice) so researchers can watch how a disease progresses and how a potential drug behaves in a living body. For investors, these models act like a realistic prototype test: strong positive results can lower the technical risk of a drug program and increase the likelihood of advancing to costly human trials, while failures can signal higher development risk.

glp-validated medical

"Bioanalytical readiness: GLP-validated bioanalytical methods completed to support"

GLP-validated means a laboratory test, method, or preclinical study has been carried out and confirmed under Good Laboratory Practice standards, a set of rules that ensure experiments are reliable, reproducible and properly documented. For investors, GLP validation is like a safety inspection for data: it makes scientific results more credible to regulators and reduces the risk that flawed or inconsistent lab work will derail a product’s approval or commercial path.

pharmacokinetic medical

"methods completed to support pharmacokinetic, biodistribution, and exposure-response"

Pharmacokinetic describes how a drug moves through and leaves the body — how it is absorbed, spread to tissues, broken down and excreted — like tracking a package from pickup to delivery and disposal. For investors, these properties determine effective dose, safety risks, how often a medicine must be taken, and how reliably it works, which in turn influence clinical trial success, regulatory approval chances, production complexity and a drug’s commercial value.

biodistribution medical

"methods completed to support pharmacokinetic, biodistribution, and exposure-response"

Biodistribution is the map of where a drug, vaccine, or diagnostic agent travels and accumulates inside the body after administration. Investors care because where a product ends up affects how well it works, what side effects it may cause, and whether regulators will approve it—similar to tracking dye in a plumbing system to find leaks or blockages; unexpected destinations can raise safety, cost, and market-adoption risks.

orphan drug designation regulatory

"HT-KIT has received Orphan Drug Designation and is designed to address cancers"

Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.

mrna medical

"HT-KIT achieved >80% reduction of KIT mRNA/protein across in-vitro systems"

mRNA, short for messenger ribonucleic acid, is a biological molecule that carries instructions from a cell’s genetic blueprint to make specific proteins — like a recipe or software code that tells a kitchen or computer what to produce. Investors care because mRNA is used as a flexible drug and vaccine platform that can be developed and scaled faster than many traditional medicines; its commercial prospects, manufacturing needs, regulatory approval path, and patent position can strongly affect a company’s value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

AI Integration Supports IND Preparation & Phase 1 Progression for Rare KIT-Driven Cancers

NEW YORK, March 4, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company advancing breakthrough therapies for diseases, today announced the deployment of the OpenAI API to support IND-enabling development of HT-KIT, its orphan-designated therapy targeting rare and aggressive KIT-driven cancers.

The OpenAI-powered API platform has been integrated into the HT-KIT development workflow to support preclinical data analysis, molecular modeling of KIT-driven pathways, and preparation of regulatory documentation ahead of IND submission.

HT-KIT results below have shown success in rare cancers 

• Potent gene-level target suppression: HT-KIT achieved >80% reduction of KIT mRNA/protein across in-vitro systems and in vivo models of systemic mastocytosis and GIST.
  
  
• Favorable tolerability in early studies: No dose-limiting toxicities observed in the reported preclinical work to date.
  
  
• Rapid anti-tumor activity: In xenograft models, statistically significant tumor-volume reduction by Day 8 was observed, accompanied by apoptotic signaling consistent with KIT pathway knock-down.
  
  
• Bioanalytical readiness: GLP-validated bioanalytical methods completed to support pharmacokinetic, biodistribution, and exposure-response analyses for IND.
  
  
• HT-KIT is advancing toward Investigational New Drug (IND) submission and Phase 1 clinical evaluation.
  
  
• HT-KIT has received Orphan Drug Designation and is designed to address cancers driven by KIT mutations, an area of significant unmet medical need.

"Hoth's integration of OpenAI's API supports execution of our IND-enabling strategy for HT-KIT as we advance toward Phase 1," said Robb Knie, Chief Executive Officer.

About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/.

Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct.

Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

Investor Contact:
LR Advisors LLC 
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-deploys-openai-api-to-advance-development-of-orphan-ht-kit-oncology-program-302702356.html

SOURCE Hoth Therapeutics, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What preclinical efficacy did Hoth report for HT-KIT (HOTH) on March 4, 2026?

HT-KIT showed >80% reduction of KIT mRNA/protein and rapid tumor reduction by Day 8. According to the company, xenograft models demonstrated statistically significant volume decreases with apoptotic signaling consistent with KIT pathway knock-down.

Has HT-KIT (HOTH) received any regulatory designations as of March 4, 2026?

HT-KIT has received Orphan Drug Designation for KIT-driven cancers. According to the company, this designation recognizes the therapy's focus on rare diseases and can offer regulatory incentives supporting development.

What safety findings did Hoth report for HT-KIT in preclinical studies?

No dose-limiting toxicities were observed in the reported preclinical work to date. According to the company, early tolerability results were favorable across the described preclinical studies.

How is Hoth using OpenAI API in HT-KIT development (HOTH)?

Hoth integrated the OpenAI API into HT-KIT workflows for preclinical analysis, molecular modeling, and regulatory documentation support. According to the company, the AI platform aids IND-enabling tasks and data interpretation.

What are the next development steps and timeline for HT-KIT (HOTH)?

HT-KIT is advancing toward IND submission and Phase 1 clinical evaluation, per the company. According to the company, completed GLP bioanalytics and preclinical data support forthcoming IND-enabling filings.